Clinical trial
A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination With Induction Chemotherapy, or Azacitidine and Idarubicin as Salvage Therapy and Idarubicin With Cytarabine or Azacitidine as Maintenance Therapy in Older Patients With Acute Myeloblastic Leukemia (AML)
NCT01067274 is registered in ClinicalTrials.gov with Acute Leukemia French Association as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination With Induction Chemotherapy, or Azacitidine and Idarubicin as Salvage Therapy and Idarubicin With Cytarabine or Azacitidine as Maintenance Therapy in Older Patients With Acute Myeloblastic Leukemia (AML)
- Lead sponsor
- Acute Leukemia French Association
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- April 30, 2010
- Completion date
- Not reported
- Enrollment
- 0 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia